|
gptkbp:instanceOf
|
gptkb:asset_management_company
|
|
gptkbp:AUM
|
over $17 billion
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focus
|
healthcare investments
biotech investments
medical device investments
pharmaceutical investments
|
|
gptkbp:foundedYear
|
1989
|
|
gptkbp:founder
|
gptkb:Samuel_Isaly
|
|
gptkbp:headquartersLocation
|
gptkb:New_York_City
|
|
gptkbp:industry
|
gptkb:biotechnology
healthcare
life sciences
|
|
gptkbp:investedIn
|
public companies
private companies
early stage
late stage
|
|
gptkbp:managingPartner
|
gptkb:Vikas_Goyal
gptkb:Peter_Thompson
gptkb:Carl_Gordon
gptkb:Jonathan_Silverstein
gptkb:Sven_Borho
Rishi Gupta
|
|
gptkbp:notableInvestment
|
gptkb:Moderna
gptkb:Sarepta_Therapeutics
gptkb:BioNTech
gptkb:Immunocore
gptkb:CRISPR_Therapeutics
gptkb:Natera
gptkb:Replimune
gptkb:Ascendis_Pharma
gptkb:Argenx
|
|
gptkbp:numberOfEmployees
|
over 100
|
|
gptkbp:officeLocation
|
gptkb:Mumbai
gptkb:San_Francisco
gptkb:Shanghai
Herzliya
|
|
gptkbp:regionServed
|
global
|
|
gptkbp:type
|
gptkb:investor
|
|
gptkbp:website
|
https://www.orbimed.com/
|
|
gptkbp:bfsParent
|
gptkb:Hemab_Therapeutics
gptkb:Scorpion_Therapeutics
gptkb:Treeline_Biosciences
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
OrbiMed
|